Interestingly, a recent large cohort study linked statin (HMG-CoA reductase inhibitors) use to a reduced risk of HCC—a finding that appears to contradict our genetic results (Choi et al., 2025). The gene discussed is HMGCR; the disease is hepatocellular carcinoma.